Physician profile
David Michael Lemchak
NPI 1184071292
$7,397.42
in general payments reported to CMS, 2019-2025
33 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,094 · 2020: $2,598 · 2021: $833 · 2022: $25.30 · 2023: $165 · 2024: $62.30 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.98 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $979.06 | 2019-2025 | Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $783.49 | 2019-2021 | |
| Janssen Biotech, INC. | $654.85 | 2019-2025 | Tremfya, Stelara, Simponi |
| Mayne Pharma Commercial LLC | $636.66 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $557.87 | 2020-2021 | |
| Pfizer INC. | $518.95 | 2019-2021 | |
| Almirall LLC | $364.35 | 2019-2020 | |
| Abbvie INC. | $302.51 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $269.80 | 2019-2025 | |
| Amgen INC. | $258.01 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $235.94 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $217.83 | 2019-2021 | |
| Lilly USA, LLC | $180.61 | 2019-2025 | Taltz, Ebglyss |
| Epi Health, LLC | $174.39 | 2019-2021 | |
| Genzyme Corporation | $145.62 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $141.70 | 2019-2025 | |
| Journey Medical Corporation | $139.93 | 2020-2025 | |
| Biofrontera INC. | $129.09 | 2019-2021 | |
| Stemline Therapeutics INC. | $117.76 | 2019 | |
| Ucb, INC. | $104.03 | 2020-2025 | Bimzelx |
| Encore Dermatology INC. | $82.58 | 2019-2020 | |
| Celgene Corporation | $77.90 | 2019 | |
| Dermira, INC. | $76.56 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $57.22 | 2020 | |
| Revance Therapeutics, INC. | $30.11 | 2025 | Daxxify |
| Promius Pharma LLC | $26.83 | 2019 | |
| Medtronic, INC. | $25.30 | 2022 | |
| Dusa Pharmaceuticals, INC. | $23.74 | 2019 | |
| Glenmark Therapeutics INC. | $23.00 | 2019 | |
| Smith+Nephew, INC. | $20.97 | 2025 | Collagenase Santyl |
| Cipher Pharmaceuticals US LLC | $15.74 | 2025 | Natroba, Spinosad |
| Aclaris Therapeutics, INC. | $13.50 | 2019 | |
| Mission Pharmacal Company | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lemchak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.